Skip to Content
You are currently on the new version of our website. Access the old version .

81 Results Found

  • Article
  • Open Access
17 Citations
7,734 Views
26 Pages

Bivalent EGFR-Targeting DARPin-MMAE Conjugates

  • Lennard Karsten,
  • Nils Janson,
  • Vadim Le Joncour,
  • Sarfaraz Alam and ,
  • Benjamin Müller,
  • Jayendrakishore Tanjore Ramanathan,
  • Pirjo Laakkonen,
  • Norbert Sewald and
  • Kristian M. Müller
  • + 4 authors+ 0 author

23 February 2022

Epidermal growth factor receptor (EGFR) is a validated tumor marker overexpressed in various cancers such as squamous cell carcinoma (SSC) of the head and neck and gliomas. We constructed protein-drug conjugates based on the anti-EGFR Designed Ankyri...

(This article belongs to the Special Issue Novel Biological Molecules for Cancer Treatments)
  • Article
  • Open Access
12 Citations
7,299 Views
20 Pages

Old Drug, New Delivery Strategy: MMAE Repackaged

  • Hanane Lahnif,
  • Tilmann Grus,
  • Evangelia-Alexandra Salvanou,
  • Elisavet Deligianni and ,
  • Dimitris Stellas,
  • Penelope Bouziotis and
  • Frank Rösch
  • + 2 authors+ 0 author

Targeting therapy is a concept that has gained significant importance in recent years, especially in oncology. The severe dose-limiting side effects of chemotherapy necessitate the development of novel, efficient and tolerable therapy approaches. In...

(This article belongs to the Special Issue Novel Researches and Perspectives on Prostate Cancer)
  • Article
  • Open Access
37 Citations
15,383 Views
21 Pages

Antibody-Drug Conjugate Using Ionized Cys-Linker-MMAE as the Potent Payload Shows Optimal Therapeutic Safety

  • Yanming Wang,
  • Lianqi Liu,
  • Shiyong Fan,
  • Dian Xiao and ,
  • Fei Xie,
  • Wei Li,
  • Wu Zhong and
  • Xinbo Zhou
  • + 3 authors+ 0 author

21 March 2020

Monomethyl auristatin E (MMAE) is the most popular and widely used cytotoxin in the development of antibody-drug conjugates (ADCs). However, current MMAE-based ADCs are all constructed using cleavable linkers, and this design concept still has insurm...

  • Article
  • Open Access
54 Citations
12,791 Views
18 Pages

23 March 2021

Monomethyl auristatin E (MMAE) is one of the most commonly used payloads for developing antibody–drug conjugates (ADC). However, limited studies have comprehensively evaluated the whole-body disposition of MMAE. Consequently, here, we have investigat...

(This article belongs to the Section Oncology)
  • Feature Paper
  • Article
  • Open Access
22 Citations
6,926 Views
12 Pages

Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy

  • Hanhee Cho,
  • Man Kyu Shim,
  • Yujeong Moon,
  • Sukyung Song and ,
  • Jinseong Kim,
  • Jiwoong Choi,
  • Jeongrae Kim,
  • Youngjoo Lee,
  • Jung Yeon Park and
  • Kwangmeyung Kim
  • + 9 authors+ 4 authors

A prodrug is bioreversible medication that is specifically converted to the active drugs by enzymes overexpressed in the tumor microenvironment, which can considerably reduce the chemotherapy-induced side effects. However, prodrug strategies usually...

(This article belongs to the Special Issue Development of Novel Tumor-Targeting Nanoparticles)
  • Article
  • Open Access
46 Citations
10,186 Views
18 Pages

Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy

  • Yanming Wang,
  • Shiyong Fan,
  • Dian Xiao,
  • Fei Xie and ,
  • Wei Li,
  • Wu Zhong and
  • Xinbo Zhou
  • + 2 authors+ 0 author

8 July 2019

Antibody-drug conjugate (ADC) is a novel efficient drug delivery system that has been successfully used in clinical practice, and it has become a research hotspot in the anti-tumor drug field. Acid-cleavable linkers were first used in clinical ADCs,...

  • Article
  • Open Access
35 Citations
8,072 Views
20 Pages

Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY®) Antibody–Drug Conjugate in Sprague Dawley Rats

  • Victor Yip,
  • M. Violet Lee,
  • Ola M. Saad,
  • Shuguang Ma and ,
  • S. Cyrus Khojasteh and
  • Ben-Quan Shen
  • + 1 author+ 0 author

23 March 2021

Polatuzumab vedotin (or POLIVY®), an antibody–drug conjugate (ADC) composed of a polatuzumab monoclonal antibody conjugated to monomethyl auristatin E (MMAE) via a cleavable dipeptide linker, has been approved by the United States Food and Drug Admin...

(This article belongs to the Section Oncology)
  • Article
  • Open Access
40 Citations
9,792 Views
21 Pages

Small Molecule-Based Prodrug Targeting Prostate Specific Membrane Antigen for the Treatment of Prostate Cancer

  • Xinning Wang,
  • Aditi Shirke,
  • Ethan Walker,
  • Rongcan Sun and ,
  • Gopolakrishnan Ramamurthy,
  • Jing Wang,
  • Lingpeng Shan,
  • Joey Mangadlao,
  • Zhipeng Dong and
  • James P. Basilion
  • + 14 authors+ 9 authors

22 January 2021

Metastatic castration-resistant prostate cancer poses a serious clinical problem with poor outcomes and remains a deadly disease. New targeted treatment options are urgently needed. PSMA is highly expressed in prostate cancer and has been an attracti...

  • Article
  • Open Access
21 Citations
12,226 Views
18 Pages

A Cell-Level Systems PK-PD Model to Characterize In Vivo Efficacy of ADCs

  • Aman P. Singh,
  • Leiming Guo,
  • Ashwni Verma,
  • Gloria Gao-Li Wong and
  • Dhaval K. Shah

Here, we have presented the development of a systems pharmacokinetics-pharmacodynamics (PK-PD) model for antibody-drug conjugates (ADCs), which uses intracellular target occupancy to drive in-vivo efficacy. The model is built based on PK and efficacy...

(This article belongs to the Special Issue Application of Translational Mathematical Modeling in Drug Development)
  • Article
  • Open Access
35 Citations
11,088 Views
17 Pages

Antibody-drug conjugates (ADCs) have demonstrated a great therapeutic potential against cancer due to their target specificity and cytotoxicity. To exert a maximum therapeutic effect on cancerous cells, we have conjugated two different payloads to di...

(This article belongs to the Special Issue Recent Advances in Therapeutic Antibody)
  • Article
  • Open Access
3 Citations
4,977 Views
19 Pages

Tumor Site-Specific Cleavage Improves the Antitumor Efficacy of Antibody–Drug Conjugates

  • Keyuan Xu,
  • Jiani Han,
  • Liu Yang,
  • Li Cao and ,
  • Shuang Li and
  • Zhangyong Hong
  • + 1 author+ 0 author

Antibody—drug conjugates (ADCs) play important roles in tumor therapy. However, traditional ADCs are limited by the extremely large molecular weight of the antibody molecules, which results in low permeability into solid tumors. The use of smal...

(This article belongs to the Section Molecular Pharmacology)
  • Article
  • Open Access
12 Citations
5,264 Views
18 Pages

Generation and Characterization of SORT1-Targeted Antibody–Drug Conjugate for the Treatment of SORT1-Positive Breast Tumor

  • Weiliang Zhuang,
  • Wei Zhang,
  • Liping Xie,
  • Lei Wang and ,
  • Yuan Li,
  • Ziyu Wang,
  • Ao Zhang,
  • Haitao Qiu,
  • Jun Feng and
  • Youjia Hu
  • + 6 authors+ 1 author

18 December 2023

Antibody–drug conjugates (ADCs) have greatly improved the outcomes of advanced breast tumors. However, the treatment of breast tumors with existing ADCs is still hindered by many issues, such as tumor antigen heterogeneity and drug resistance....

(This article belongs to the Special Issue Therapeutic Antibody Development: What Are We Learning along the Way? 2.0)
  • Article
  • Open Access
29 Citations
12,554 Views
20 Pages

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer

  • Efrat T. Harel,
  • Penelope M. Drake,
  • Robyn M. Barfield,
  • Irene Lui and ,
  • Shauna Farr-Jones,
  • Laura Van’t Veer,
  • Zev J. Gartner,
  • Evan M. Green,
  • André Luiz Lourenço and
  • Charles S. Craik
  • + 8 authors+ 3 authors

5 November 2019

A promising molecular target for aggressive cancers is the urokinase receptor (uPAR). A fully human, recombinant antibody that binds uPAR to form a stable complex that blocks uPA-uPAR interactions (2G10) and is internalized primarily through endocyto...

  • Article
  • Open Access
9 Citations
4,810 Views
17 Pages

FGF2-Derived PeptibodyF2-MMAE Conjugate for Targeted Delivery of Cytotoxic Drugs into Cancer Cells Overexpressing FGFR1

  • Karolina Jendryczko,
  • Julia Chudzian,
  • Natalia Skinder,
  • Łukasz Opaliński and ,
  • Jakub Rzeszótko,
  • Antoni Wiedlocha,
  • Jacek Otlewski and
  • Anna Szlachcic
  • + 3 authors+ 0 author

15 October 2020

Fibroblast growth factor receptors (FGFRs) are emerging targets for directed cancer therapy. Presented here is a new FGFR1-targeting conjugate, the peptibodyF2, which employs peptibody, a fusion of peptide and the Fc fragment of human IgG as a select...

  • Article
  • Open Access
1 Citations
4,068 Views
15 Pages

Assessment of ADC Higher Order Structure Through 2D NMR Analysis

  • Emily M. Grasso,
  • Angela N. Marquard,
  • Zachary Sparta,
  • David Fry and
  • Nareshkumar Jain

20 November 2025

Antibody–drug conjugates (ADCs) represent a growing class of important chemotherapeutic molecules. Our understanding of the physical properties of the antibody, linker, and payload is still quite limited, but a better understanding may lead to...

(This article belongs to the Special Issue New Trends of Nuclear Magnetic Resonance Spectroscopy (NMR) in Chemical and Biomolecular Studies)
  • Communication
  • Open Access
18 Citations
7,244 Views
16 Pages

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells

  • Anna M. Serwotka-Suszczak,
  • Alicja M. Sochaj-Gregorczyk,
  • Jerzy Pieczykolan,
  • Daniel Krowarsch and ,
  • Filip Jelen and
  • Jacek Otlewski
  • + 1 author+ 0 author

14 February 2017

Antibody-drug conjugates (ADCs) have recently emerged as efficient and selective cancer treatment therapeutics. Currently, alternative forms of drug carriers that can replace monoclonal antibodies are under intensive investigation. Here, a cytotoxic...

(This article belongs to the Section Molecular Recognition)
  • Feature Paper
  • Article
  • Open Access
3 Citations
1,977 Views
20 Pages

Early Development of an Innovative Nanoparticle-Based Multimodal Tool for Targeted Drug Delivery: A Step-by-Step Approach

  • Chiara Barattini,
  • Angela Volpe,
  • Daniele Gori,
  • Daniele Lopez and ,
  • Alfredo Ventola,
  • Stefano Papa,
  • Mariele Montanari and
  • Barbara Canonico
  • + 3 authors+ 0 author

3 May 2025

Prostate cancer is the most common tumor in men in developed countries and it often responds poorly to conventional treatments. Monoclonal antibody (MoAb) therapy, for this pathology, has grown tremendously in the past decades, exploiting naked and c...

  • Article
  • Open Access
4 Citations
5,607 Views
24 Pages

Aminooxy Click Modification of a Periodate-Oxidized Immunoglobulin G: A General Approach to Antibody–Drug Conjugates with Dye-Mediated Expeditious Stoichiometry Control

  • Ksenia A. Sapozhnikova,
  • Evgeny L. Gulyak,
  • Vladimir A. Brylev,
  • Vsevolod A. Misyurin and ,
  • Sergey D. Oreshkov,
  • Anastasiya V. Alexeeva,
  • Dmitry Yu. Ryazantsev,
  • Maria A. Simonova,
  • Ekaterina V. Ryabukhina and
  • Vladimir A. Korshun
  • + 12 authors+ 7 authors

A universal approach to the construction of antibody–drug conjugates (ADCs) has been developed. It relies on periodate oxidation of naturally present glycans of immunoglobulin G, followed by oxime ligation and, optionally, copper(I)-catalyzed a...

(This article belongs to the Special Issue Macrocycles as Catalysts or Drug Carriers)
  • Article
  • Open Access
25 Citations
6,566 Views
18 Pages

PEG Linker Improves Antitumor Efficacy and Safety of Affibody-Based Drug Conjugates

  • Qiyu Li,
  • Wenjing Li,
  • Keyuan Xu,
  • Yutong Xing and ,
  • Haobo Shi,
  • Zhe Jing,
  • Shuang Li and
  • Zhangyong Hong
  • + 3 authors+ 0 author

3 February 2021

Antibody drug conjugates (ADCs) have become an important modality of clinical cancer treatment. However, traditional ADCs have some limitations, such as reduced permeability in solid tumors due to the high molecular weight of monoclonal antibodies, d...

(This article belongs to the Section Molecular Pharmacology)
  • Article
  • Open Access
10 Citations
8,668 Views
31 Pages

Branched Linkers for Homogeneous Antibody-Drug Conjugates: How Long Is Long Enough?

  • Evgeny L. Gulyak,
  • Olga A. Komarova,
  • Yury A. Prokopenko,
  • Elina A. Faizullina and ,
  • Diana M. Malabuiok,
  • Aigul R. Ibragimova,
  • Yuliana A. Mokrushina,
  • Oxana V. Serova,
  • Galina P. Popova and
  • Ksenia A. Sapozhnikova
  • + 13 authors+ 8 authors

12 December 2024

Homogeneous antibody–drug conjugates (ADCs) exhibit significantly improved pharmacological properties compared to their heterogeneous counterparts. Site-specific conjugation of the payload to the IgG required for homogeneity can be achieved usi...

(This article belongs to the Section Molecular Immunology)
  • Article
  • Open Access
2 Citations
914 Views
24 Pages

Integrated Design of Cooperative Detection and Guidance Considering Equal Numbers of Aircraft on Both Sides

  • Jin Wang,
  • Yang Guo,
  • Yongchao Wang,
  • Fucong Liu and ,
  • Zhengquan Liu,
  • Haonan Wang and
  • Chengyi Zhang
  • + 2 authors+ 0 author

17 December 2025

In the scenario where the number of interceptors is equal to the number of target aircraft, and recognizing that the geometric configuration of interceptors during their maneuver towards targets affects detection effectiveness and guidance accuracy,...

(This article belongs to the Section Aeronautics)
  • Communication
  • Open Access
6 Citations
3,670 Views
14 Pages

Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker

  • Vladimir A. Brylev,
  • Ekaterina V. Ryabukhina,
  • Ekaterina V. Nazarova,
  • Nadezhda S. Samoylenkova and ,
  • Evgeny L. Gulyak,
  • Ksenia A. Sapozhnikova,
  • Fatima M. Dzarieva,
  • Alexey V. Ustinov,
  • Igor N. Pronin and
  • Vladimir A. Korshun
  • + 10 authors+ 5 authors

Background/Objectives: Targeted delivery of chemotherapeutic agents is a well-established approach to cancer therapy. Antibody–drug conjugates (ADCs) typically carry toxic payloads attached to a tumor-associated antigen-targeting IgG antibody v...

(This article belongs to the Special Issue Nucleic-Acid-Based Strategies and Nanotechnology Applications for Targeted Therapy)
  • Article
  • Open Access
29 Citations
9,507 Views
24 Pages

21 December 2023

In this study, we designed a multi-sensor fusion technique based on deep reinforcement learning (DRL) mechanisms and multi-model adaptive estimation (MMAE) for simultaneous localization and mapping (SLAM). The LiDAR-based point-to-line iterative clos...

(This article belongs to the Section Sensors and Robotics)
  • Article
  • Open Access
16 Citations
7,472 Views
16 Pages

Oncofetal Chondroitin Sulfate Is a Highly Expressed Therapeutic Target in Non-Small Cell Lung Cancer

  • Htoo Zarni Oo,
  • Zoltan Lohinai,
  • Nastaran Khazamipour,
  • Joey Lo and ,
  • Gunjan Kumar,
  • Jessica Pihl,
  • Hans Adomat,
  • Noushin Nabavi,
  • Hakhamanesh Behmanesh and
  • Mads Daugaard
  • + 19 authors+ 14 authors

6 September 2021

Broad-spectrum therapeutics in non-small cell lung cancer (NSCLC) are in demand. Most human solid tumors express proteoglycans modified with distinct oncofetal chondroitin sulfate (CS) chains that can be detected and targeted with recombinant VAR2CSA...

(This article belongs to the Section Cancer Biomarkers)
  • Article
  • Open Access
16 Citations
5,558 Views
16 Pages

25 August 2017

Electrochemical model-based condition monitoring of a Li-Ion battery using an experimentally identified battery model and Hybrid Pulse Power Characterization (HPPC) cycle is presented in this paper. LiCoO2 cathode chemistry was chosen in this work du...

  • Article
  • Open Access
50 Citations
20,633 Views
30 Pages

We hypothesize that different routes of administration may lead to altered pharmacokinetics/pharmacodynamics (PK/PD) behavior of antibody-drug conjugates (ADCs) and may help to improve their therapeutic index. To evaluate this hypothesis, here we per...

(This article belongs to the Special Issue Antibody Drug Conjugates: Unlocking the Future of Immunotherapies)
  • Article
  • Open Access
12 Citations
3,600 Views
14 Pages

Time-Prolonged Release of Tumor-Targeted Protein–MMAE Nanoconjugates from Implantable Hybrid Materials

  • Naroa Serna,
  • Aïda Falgàs,
  • Annabel García-León,
  • Ugutz Unzueta and ,
  • Yáiza Núñez,
  • Alejandro Sánchez-Chardi,
  • Carlos Martínez-Torró,
  • Ramón Mangues,
  • Esther Vazquez and
  • Antonio Villaverde
  • + 6 authors+ 1 author

The sustained release of small, tumor-targeted cytotoxic drugs is an unmet need in cancer therapies, which usually rely on punctual administration regimens of non-targeted drugs. Here, we have developed a novel concept of protein–drug nanoconju...

(This article belongs to the Special Issue Chemically Enhanced Peptide and Protein Therapeutics)
  • Article
  • Open Access
8 Citations
3,517 Views
17 Pages

A Synergistic Strategy Combining Chemotherapy and Photodynamic Therapy to Eradicate Prostate Cancer

  • Aditi A. Shirke,
  • Ethan Walker,
  • Sriprada Chavali,
  • Gopalakrishnan Ramamurthy and ,
  • Lifang Zhang,
  • Abhiram Panigrahi,
  • James P. Basilion and
  • Xinning Wang
  • + 3 authors+ 0 author

Prostate cancer is the most prevalent cancer among men in the United States and is a leading cause of cancer-related death. Prostate specific membrane antigen (PSMA) has been established as a biomarker for prostate cancer diagnosis and treatment. Thi...

(This article belongs to the Special Issue Molecular Advances in Oncologic Photodynamic Therapy)
  • Article
  • Open Access
4 Citations
2,749 Views
9 Pages

Radiological Outcome of Middle Meningeal Artery Embolization in Relation to Chronic Subdural Hematoma Cause and Architecture

  • Ahmed Abdelghafar,
  • Andrew Falzon,
  • Eef J. Hendriks,
  • Ivan Radovanovic and ,
  • Hugo Andrade,
  • Joanna D. Schaafsma and
  • Pascal J. Mosimann
  • + 2 authors+ 0 author

30 October 2024

Background/Objectives: MMAE (middle meningeal artery embolization) has emerged as a potential effective treatment for cSDH (chronic subdural hematoma). In this study, MMAE efficiency with regards to cSDH cause and architecture was explored. The compa...

(This article belongs to the Special Issue The Latest Exploration of Cerebrovascular Diseases: From Preclinical Research to Treatment)
  • Article
  • Open Access
9 Citations
4,423 Views
16 Pages

Tumor-Targeted Cell-Penetrating Peptides Reveal That Monomethyl Auristatin E Temporally Modulates the Tumor Immune Microenvironment

  • Mahsa Mortaja,
  • Marcus M. Cheng,
  • Alina Ali,
  • Jacqueline Lesperance and ,
  • Dina V. Hingorani,
  • Mike M. Allevato,
  • Kanika Dhawan,
  • Maria F. Camargo,
  • Rana R. McKay and
  • Sunil J. Advani
  • + 7 authors+ 2 authors

27 November 2024

Chemotherapies remain standard therapy for cancers but have limited efficacy and cause significant side effects, highlighting the need for targeted approaches. In the progression of cancer, tumors increase matrix metalloproteinase (MMP) activity. Lev...

  • Article
  • Open Access
17 Citations
4,146 Views
16 Pages

Improved Multiple-Model Adaptive Estimation Method for Integrated Navigation with Time-Varying Noise

  • Jinhao Song,
  • Jie Li,
  • Xiaokai Wei,
  • Chenjun Hu and ,
  • Zeyu Zhang,
  • Lening Zhao and
  • Yubing Jiao
  • + 2 authors+ 0 author

10 August 2022

The accurate noise parameter is essential for the Kalman filter to obtain optimal estimates. However, problems such as variations in the noise environment and measurement anomalies can cause degradation of estimation accuracy or even divergence. The...

(This article belongs to the Section Navigation and Positioning)
  • Abstract
  • Open Access
1,408 Views
1 Page

In Vitro Characterization of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Breast Cancer Cells

  • Isabella Damiani,
  • Silvia Castiglioni,
  • Valentina Rusconi,
  • Clara Rossi and ,
  • Alberto Corsini and
  • Stefano Bellosta
  • + 1 author+ 0 author

Antibody-drug conjugates (ADCs) are used in anticancer therapy with some limitations due to their molecular properties. An alternative to monoclonal antibodies is the affibody, composed of 58 amino acids, with lower binding affinities, small size, an...

(This article belongs to the Proceedings of The 1st International Electronic Conference on Biomedicine)
  • Article
  • Open Access
11 Citations
6,249 Views
13 Pages

HER2-targeting therapies have advanced breast cancer treatment over the past decade. Clinically, eligibility for HER2 therapies is determined by assessing HER2 levels on tumor cell surfaces through immunohistochemistry or by gene regulation through f...

(This article belongs to the Section Biologics and Biosimilars)
  • Article
  • Open Access
7 Citations
4,213 Views
18 Pages

Targeting fibroblast growth factor receptor 1 (FGFR1) is a promising therapeutic strategy for various cancers associated with alterations in the FGFR1 gene. In this study, we developed a highly cytotoxic bioconjugate based on fibroblast growth factor...

(This article belongs to the Collection Feature Papers in Molecular Pathology, Diagnostics, and Therapeutics)
  • Article
  • Open Access
44 Citations
13,150 Views
13 Pages

Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility

  • Tero Satomaa,
  • Henna Pynnönen,
  • Anja Vilkman,
  • Titta Kotiranta and ,
  • Virve Pitkänen,
  • Annamari Heiskanen,
  • Bram Herpers,
  • Leo S. Price,
  • Jari Helin and
  • Juhani Saarinen
  • + 5 authors+ 0 author

22 March 2018

Antibody-drug conjugates (ADCs) offer a combination of antibody therapy and specific delivery of potent small-molecule payloads to target cells. The properties of the ADC molecule are determined by the balance of its components. The efficacy of the p...

(This article belongs to the Special Issue Antibody Drug Conjugates)
  • Review
  • Open Access
199 Citations
26,283 Views
17 Pages

HER2 Directed Antibody-Drug-Conjugates beyond T-DM1 in Breast Cancer

  • Gabriel Rinnerthaler,
  • Simon Peter Gampenrieder and
  • Richard Greil

Since the discovery of the human epidermal growth factor receptor 2 (HER2) as an oncogenic driver in a subset of breast cancers and the development of HER2 directed therapies, the prognosis of HER2 amplified breast cancers has improved meaningfully....

(This article belongs to the Special Issue Receptor-Targeted Cancer Therapy)
  • Article
  • Open Access
51 Citations
11,481 Views
22 Pages

21 June 2019

Nanoparticle carriers offer the possibility of enhanced delivery of therapeutic payloads in tumor tissues due to tumor-selective accumulation through the enhanced permeability and retention effect (EPR). Gold nanoparticles (AuNP), in particular, poss...

(This article belongs to the Special Issue Therapeutic Monoclonal Antibodies and Antibody Products, Their Optimization and Drug Design in Cancers)
  • Article
  • Open Access
13 Citations
6,247 Views
14 Pages

Design and In Vitro Evaluation of a Cytotoxic Conjugate Based on the Anti-HER2 Affibody Fused to the Fc Fragment of IgG1

  • Alicja M. Sochaj-Gregorczyk,
  • Patryk Ludzia,
  • Emilia Kozdrowska,
  • Piotr Jakimowicz and ,
  • Aleksandra Sokolowska-Wedzina and
  • Jacek Otlewski
  • + 1 author+ 0 author

In our previous work we demonstrated that a small protein called affibody can be used for a cytotoxic conjugate development. The anti-HER2 affibody was armed with one moiety of a highly potent auristatin E and specifically killed HER2-positive cancer...

(This article belongs to the Special Issue Tumor Targeting Therapy and Selective Killing)
  • Article
  • Open Access
6 Citations
2,948 Views
16 Pages

The equality of healthcare services has been a focus among researchers and policymakers. The maximal accessibility equality (MAE) model is a widely used location-allocation model for the optimization of the accessibility equality of facilities. Howev...

  • Article
  • Open Access
14 Citations
4,685 Views
11 Pages

14 April 2022

Pancreatic cancer is a highly fatal disease that is becoming an increasingly leading cause of cancer-related deaths. In clinic, the most effective approach to treat pancreatic cancers is the combination treatment of several chemotherapeutic drugs, in...

(This article belongs to the Special Issue Nanotechnology to Overcome World’s Most Critical Health Issues: Liposomes and beyond—a Themed Issue Dedicated to Professor Yechezkel Barenholz)
  • Article
  • Open Access
13 Citations
9,356 Views
12 Pages

Hydrophilic Monomethyl Auristatin E Derivatives as Novel Candidates for the Design of Antibody-Drug Conjugates

  • Filip S. Ekholm,
  • Suvi-Katriina Ruokonen,
  • Marina Redón,
  • Virve Pitkänen and ,
  • Anja Vilkman,
  • Juhani Saarinen,
  • Jari Helin,
  • Tero Satomaa and
  • Susanne K. Wiedmer
  • + 4 authors+ 0 author

Antibody-drug conjugates (ADCs) are promising state-of-the-art biopharmaceutical drugs for selective drug-delivery applications and the treatment of diseases such as cancer. The idea behind the ADC technology is remarkable as it combines the highly s...

(This article belongs to the Special Issue Five Years of Separations: Feature Paper 2018)
  • Article
  • Open Access
8 Citations
6,079 Views
20 Pages

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells

  • Isabella Damiani,
  • Silvia Castiglioni,
  • Alicja Sochaj-Gregorczyk,
  • Fabrizia Bonacina and ,
  • Irma Colombo,
  • Valentina Rusconi,
  • Jacek Otlewski,
  • Alberto Corsini and
  • Stefano Bellosta
  • + 4 authors+ 0 author

7 August 2021

A promising approach for the development of high-affinity tumor targeting ADCs is the use of engineered protein drugs, such as affibody molecules, which represent a valuable alternative to monoclonal antibodies (mAbs) in cancer-targeted therapy. We d...

(This article belongs to the Section Cancer Biology)
  • Article
  • Open Access
519 Views
14 Pages

Preserving Continuity of Cancer Therapy in Patients with Hematologic Malignancies and Chronic Subdural Hematomas: Comparative Outcomes of Middle Meningeal Artery Embolization and Surgery

  • Esteban Ramirez-Ferrer,
  • Juan P. Zuluaga-Garcia,
  • Maria A. Sierra,
  • Danielle Hammond and ,
  • Hagop M. Kantarjian,
  • Jeffrey S. Weinberg,
  • Chibawanye I. Ene,
  • Shaan M. Raza,
  • Frederick F. Lang and
  • Christopher C. Young
  • + 7 authors+ 2 authors

1 September 2026

Background/Objective: Hematologic cancer patients are at high risk of developing chronic subdural hematomas (cSDH), and traditional treatment with surgery is potentially risky in this patient population, with associated coagulopathy and thrombocytope...

(This article belongs to the Section Methods and Technologies Development)
  • Article
  • Open Access
5 Citations
5,076 Views
25 Pages

Neuropharmacological Activity of the Acetonic Extract of Malpighia mexicana A. Juss. and Its Phytochemical Profile

  • Dante Avilés-Montes,
  • David Osvaldo Salinas-Sánchez,
  • César Sotelo-Leyva,
  • Alejandro Zamilpa and ,
  • Franceli Itzel Batalla-Martinez,
  • Rodolfo Abarca-Vargas,
  • Juan Manuel Rivas-González,
  • Óscar Dorado,
  • Rodolfo Figueroa-Brito and
  • Manasés González-Cortazar
  • + 7 authors+ 2 authors

10 October 2023

Mental and neurological disorders are conditions that affect thoughts, emotions, behavior, and relationships. Malpighia mexicana A. Juss. is a plant used in Mexican traditional medicine for the treatment of such disorders. This work aimed to investig...

(This article belongs to the Topic Natural Products and Drug Discovery)
  • Article
  • Open Access
9 Citations
5,959 Views
16 Pages

Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines

  • Ariana Abawi,
  • Xiaoyi Wang,
  • Julien Bompard,
  • Anna Bérot and ,
  • Valentina Andretto,
  • Leslie Gudimard,
  • Chloé Devillard,
  • Emma Petiot,
  • Benoit Joseph and
  • Ofelia Maniti
  • + 8 authors+ 3 authors

Novel nanomedicines have been engineered to deliver molecules with therapeutic potentials, overcoming drawbacks such as poor solubility, toxicity or short half-life. Lipid-based carriers such as liposomes represent one of the most advanced classes of...

(This article belongs to the Special Issue Nanostructures Applied to Drug Delivery and Diagnosis)
  • Article
  • Open Access
19 Citations
8,358 Views
18 Pages

The Antitumor Activity of TCR-Mimic Antibody-Drug Conjugates (TCRm-ADCs) Targeting the Intracellular Wilms Tumor 1 (WT1) Oncoprotein

  • Ying Shen,
  • Yi-Ming Li,
  • Jing-Jing Zhou,
  • Zhan Zhou and ,
  • Ying-Chun Xu,
  • Wen-Bin Zhao and
  • Shu-Qing Chen
  • + 2 authors+ 0 author

12 August 2019

Wilms tumor 1 (WT1) oncoprotein is an intracellular oncogenic transcription factor which is barely expressed in normal adult tissues but over expressed in a variety of leukemias and solid cancers. WT1-derived HLA-A*02:01 T cell epitope, RMFPNAPYL (RM...

(This article belongs to the Special Issue New Strategies in Cancer Pharmacotherapy: Development of Hormonal Antineoplastic Drugs, Cytotoxic Drugs and Targeted Therapies)
  • Article
  • Open Access
2 Citations
2,781 Views
20 Pages

Detection of Chatter in Machining Processes by the Multiscale Maximum Approximate Entropy and Continuous Wavelet Transform

  • Daniel Pérez-Canales,
  • Juan Carlos Jáuregui-Correa,
  • José Álvarez-Ramírez and
  • Luciano Vela-Martínez

14 February 2025

Chatter is a complex dynamic instability in machining processes and presents nonlinear and nonstationary behavior. Detection of this phenomenon before a catastrophic failure occurs has great importance in the industry today. This behavior demands onl...

  • Review
  • Open Access
2 Citations
2,364 Views
37 Pages

Chronic Subdural Hematoma: Pathophysiology, Diagnosis, and the Emerging Role of Middle Meningeal Artery Embolization

  • Nikodem Kuczyński,
  • Dawid Pilewski,
  • Edyta Zomkowska,
  • Wojciech Pulka and
  • Mariusz Sowa

27 May 2026

Chronic subdural hematoma (CSDH) is a common neurological condition, particularly in the elderly, characterized by a complex pathophysiology involving inflammation, angiogenesis, and recurrent microhemorrhages rather than a purely mechanical process....

(This article belongs to the Section Clinical Neurology)
  • Article
  • Open Access
67 Citations
14,727 Views
19 Pages

Antibody-drug conjugates (ADCs), designed to selectively deliver cytotoxic agents to antigen-bearing cells, are poised to become an important class of cancer therapeutics. Human epithelial growth factor receptor (HER2) is considered an effective targ...

(This article belongs to the Section Biochemistry)
  • Article
  • Open Access
1 Citations
1,767 Views
25 Pages

Targeting Prostate Cancer Cells Using Anti-Sortilin and Anti-Syndecan-1 Antibody Drug Conjugates

  • Ka Lok Li,
  • Shane M. Hickey,
  • Hugo Albrecht,
  • Jessica M. Logan and ,
  • Joanna Lazniewska,
  • Courtney R. Moore,
  • Robert D. Brooks,
  • Ian R. D. Johnson,
  • John J. O’Leary and
  • Douglas A. Brooks
  • + 5 authors+ 0 author

18 November 2025

Prostate cancer tissue usually involves either well formed glands, poorly formed glands or a combination of the two morphologies, which can be correlated with metabolic differences and tumor heterogeneity. This is particularly important for metastati...

(This article belongs to the Section Molecular Pharmacology)

of 2